Design Therapeutics to Participate in Leerink’s Global Healthcare Conference
Design Therapeutics (Nasdaq: DSGN), a clinical-stage biotechnology company focused on developing treatments for serious degenerative genetic diseases, has announced its upcoming participation in Leerink's Global Healthcare Conference. The company's management will engage in a fireside chat scheduled for March 10, 2025, at 1:40 p.m. ET in Miami.
The event will be accessible through a live webcast, available on the company's website at www.designtx.com in the investors section. The presentation recording will remain archived and available for viewing for a minimum of 30 days following the event.
Design Therapeutics (Nasdaq: DSGN), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di trattamenti per gravi malattie genetiche degenerative, ha annunciato la sua prossima partecipazione alla Global Healthcare Conference di Leerink. La direzione dell'azienda parteciperà a una chiacchierata informale programmata per il 10 marzo 2025, alle 13:40 ET a Miami.
L'evento sarà accessibile tramite una diretta web, disponibile sul sito web dell'azienda all'indirizzo www.designtx.com nella sezione investitori. La registrazione della presentazione rimarrà archiviata e disponibile per la visione per un minimo di 30 giorni dopo l'evento.
Design Therapeutics (Nasdaq: DSGN), una compañía biotecnológica en etapa clínica enfocada en desarrollar tratamientos para enfermedades genéticas degenerativas graves, ha anunciado su próxima participación en la Global Healthcare Conference de Leerink. La dirección de la compañía participará en una charla informal programada para el 10 de marzo de 2025, a la 1:40 p.m. ET en Miami.
El evento será accesible a través de una transmisión en vivo, disponible en el sitio web de la compañía en www.designtx.com en la sección de inversores. La grabación de la presentación permanecerá archivada y disponible para su visualización durante un mínimo de 30 días después del evento.
Design Therapeutics (Nasdaq: DSGN)는 심각한 퇴행성 유전 질환 치료제를 개발하는 임상 단계의 생명공학 회사로, Leerink의 글로벌 헬스케어 컨퍼런스에 참여할 예정이라고 발표했습니다. 회사 경영진은 2025년 3월 10일 오후 1시 40분 ET에 마이애미에서 예정된 파이어사이드 챗에 참여할 것입니다.
이번 행사는 회사 웹사이트 www.designtx.com의 투자자 섹션을 통해 실시간 웹캐스트로 접근할 수 있습니다. 발표 녹화는 행사 후 최소 30일 동안 아카이브되어 시청할 수 있습니다.
Design Therapeutics (Nasdaq: DSGN), une entreprise de biotechnologie en phase clinique axée sur le développement de traitements pour des maladies génétiques dégénératives graves, a annoncé sa prochaine participation à la Global Healthcare Conference de Leerink. La direction de l'entreprise participera à une discussion informelle prévue pour le 10 mars 2025 à 13h40 ET à Miami.
L'événement sera accessible via un webinaire en direct, disponible sur le site web de l'entreprise à l'adresse www.designtx.com dans la section investisseurs. L'enregistrement de la présentation restera archivé et disponible à la visualisation pendant un minimum de 30 jours après l'événement.
Design Therapeutics (Nasdaq: DSGN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Behandlungen für schwere degenerative genetische Erkrankungen konzentriert, hat seine bevorstehende Teilnahme an der Global Healthcare Conference von Leerink bekannt gegeben. Das Management des Unternehmens wird an einem informellen Gespräch teilnehmen, das für den 10. März 2025 um 13:40 Uhr ET in Miami geplant ist.
Die Veranstaltung wird über einen Live-Webcast zugänglich sein, der auf der Website des Unternehmens unter www.designtx.com im Investorenbereich verfügbar ist. Die Aufzeichnung der Präsentation wird archiviert und für mindestens 30 Tage nach der Veranstaltung zur Verfügung stehen.
- None.
- None.
CARLSBAD, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during Leerink’s Global Healthcare Conference on Monday, March 10, 2025, at 1:40 p.m. ET in Miami.
A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation.
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its GeneTAC® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in myotonic dystrophy type-1 and Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
FAQ
When is Design Therapeutics (DSGN) presenting at Leerink's Global Healthcare Conference 2025?
How can investors watch Design Therapeutics' (DSGN) presentation at the Leerink Conference?
How long will Design Therapeutics' (DSGN) Leerink Conference presentation be available for viewing?
What type of presentation will Design Therapeutics (DSGN) give at the Leerink Healthcare Conference?
